中国现代医学杂志2017，Vol.27Issue(3)：93-96,4.DOI:10.3969/j.issn.1005-8982.2017.03.019
脾多肽联合化疗治疗乳腺癌的临床疗效观察
Clinical efficacy of lienal polypeptide in adjuvant chemotherapy of breast cancer
王丹丹 1陈伟贤 2夏文晋 3李建4
作者信息
- 1. 南京医科大学第一临床医学院,江苏南京210029
- 2. 江苏省常州市第二人民医院乳腺外科,江苏常州213000
- 3. 南京医科大学公共卫生学院,江苏南京210009
- 4. 江苏省肿瘤医院乳腺外科,江苏南京210009
- 折叠
摘要
Abstract
Objective To evaluate the clinical effects of lienal polypeptide in postoperative adjuvant chemotherapy of breast cancer.Methods Fifty-three breast cancer patients intended to have adjuvant chemotherapy were randomly divided into observation group (27 cases) and control group (26 cases).The patients in the observation group were treated with chemotherapy and lienal polypeptide,whereas those in the control group only received chemotherapy.Then adverse reactions,proportions of T lymphocyte subsets in peripheral blood,and KPS for life quality were analyzed and compared between the two groups.Results The incidences of severe granulocytopenia,anemia and thrombopenia in the observation group were significantly lower than those in control group.The proportions of CD3+,CD4+T lymphocytes and CD4/CD8 ratio were higher in the observation group,while CD8+T lymphocytes were fewer in the observation group in comparison to the control group.According to the average KPS score,the patients in the observation group had better quality of life than those in the control group.Conclusions Application of lienal polypeptide during postoperative adjuvant chemotherapy for breast cancer can effectively reduce myelosuppression,enhance immunologic response and increase life quality.关键词
乳腺癌/化疗/血液毒性/免疫/卡氏评分Key words
breast cancer/chemotherapy/hematologic toxicity/immunity/Karnofsky分类
医药卫生引用本文复制引用
王丹丹,陈伟贤,夏文晋,李建..脾多肽联合化疗治疗乳腺癌的临床疗效观察[J].中国现代医学杂志,2017,27(3):93-96,4.
